RadNet (NASDAQ:RDNT) Issues Earnings Results

RadNet (NASDAQ:RDNT - Get Free Report) issued its quarterly earnings data on Thursday. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.01, Zacks reports. The business had revenue of $477.10 million for the quarter, compared to the consensus estimate of $459.42 million. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. RadNet updated its FY 2025 guidance to EPS.

RadNet Trading Down 8.3 %

Shares of NASDAQ RDNT traded down $4.62 on Monday, reaching $50.85. 1,436,810 shares of the company traded hands, compared to its average volume of 861,970. The stock has a market capitalization of $3.76 billion, a PE ratio of -726.32 and a beta of 1.79. RadNet has a fifty-two week low of $42.45 and a fifty-two week high of $93.65. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average of $65.43 and a 200 day moving average of $69.09.

Wall Street Analyst Weigh In

RDNT has been the topic of a number of recent research reports. Barclays reduced their target price on shares of RadNet from $85.00 to $74.00 and set an "overweight" rating on the stock in a report on Wednesday, January 22nd. Jefferies Financial Group reduced their price objective on shares of RadNet from $100.00 to $80.00 and set a "buy" rating on the stock in a research note on Wednesday, January 15th. Finally, Truist Financial restated a "buy" rating and set a $88.00 target price (down previously from $94.00) on shares of RadNet in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $75.50.

Remove Ads

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.